Literature DB >> 9569052

Independent prognostic importance of microvessel density in endometrial carcinoma.

H B Salvesen1, O E Iversen, L A Akslen.   

Abstract

Angiogenesis is thought to be an important factor for tumour growth and metastatic spread, and microvessel counts may provide useful prognostic information for several tumour types. To investigate the prognostic impact of angiogenesis in endometrial carcinoma patients, the intratumour microvessel density, which was determined immunohistochemically, has been related to survival. Sixty patients with endometrial carcinoma with long (median 19 years) and complete follow-up have been studied. Patients with increased mean microvessel density (MVDmean > 68 mm2) had a significantly shorter 5-year survival compared with the rest (57% vs 90%, P = 0.004). In multivariate survival analyses, MVDmean had an independent prognostic impact (P = 0.03) when FIGO stage, histological type, histological grade as well as nuclear p53 protein expression was adjusted for. These findings indicate that intratumour microvessel density may contribute additional prognostic information to that obtained from the known risk factors and may be helpful in identifying endometrial carcinoma patients at high risk for disease progression.

Entities:  

Mesh:

Year:  1998        PMID: 9569052      PMCID: PMC2150144          DOI: 10.1038/bjc.1998.189

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

Review 1.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 2.  Endometrial carcinoma.

Authors:  P G Rose
Journal:  N Engl J Med       Date:  1996-08-29       Impact factor: 91.245

3.  Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer.

Authors:  T Paulsen; T Aas; A L Børresen; J E Varhaug; P E Lønning; L A Akslen
Journal:  Int J Cancer       Date:  1997-02-20       Impact factor: 7.396

4.  p53 as a prognostic indicator in endometrial cancer.

Authors:  J P Geisler; M C Wiemann; Z Zhou; G A Miller; H E Geisler
Journal:  Gynecol Oncol       Date:  1996-05       Impact factor: 5.482

5.  Angiogenesis factor in endometrial carcinoma: a new prognostic indicator?

Authors:  C V Kirschner; J M Alanis-Amezcua; V G Martin; N Luna; E Morgan; J J Yang; E L Yordan
Journal:  Am J Obstet Gynecol       Date:  1996-06       Impact factor: 8.661

6.  Endometrial adenocarcinoma in Norway. A study of a total population.

Authors:  V M Abeler; K E Kjørstad
Journal:  Cancer       Date:  1991-06-15       Impact factor: 6.860

7.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

8.  Microvessel count predicts metastatic disease and survival in non-small cell lung cancer.

Authors:  G Fontanini; D Bigini; S Vignati; F Basolo; A Mussi; M Lucchi; S Chine; C A Angeletti; A L Harris; G Bevilacqua
Journal:  J Pathol       Date:  1995-09       Impact factor: 7.996

9.  Clinicopathological characteristics of p53 overexpression in endometrial cancers.

Authors:  M Inoue; A Okayama; M Fujita; T Enomoto; M Sakata; O Tanizawa; H Ueshima
Journal:  Int J Cancer       Date:  1994-07-01       Impact factor: 7.396

10.  Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma.

Authors:  R Soong; S Knowles; K E Williams; I G Hammond; S J Wysocki; B J Iacopetta
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more
  5 in total

Review 1.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

Authors:  D Scott McMeekin; Michael W Sill; Doris Benbrook; Kathleen M Darcy; Deborah J Stearns-Kurosawa; Lynne Eaton; S Diane Yamada
Journal:  Gynecol Oncol       Date:  2007-02-15       Impact factor: 5.482

Review 3.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

Review 4.  Recent Advances in Endometrial Cancer.

Authors:  Arthur-Quan Tran; Paola Gehrig
Journal:  F1000Res       Date:  2017-01-27

5.  The cytosol activity of thymidine phosphorylase in endometrial cancer.

Authors:  Elzbieta Miszczak-Zaborska; Robert Kubiak; Andrzej Bieńkiewicz; Jacek Bartkowiak
Journal:  J Exp Clin Cancer Res       Date:  2008-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.